WallStreetZenWallStreetZen

NASDAQ: AMGN
Amgen Inc Stock

Open Broker Account
$285.57-0.19 (-0.07%)
Updated Dec 8, 2022
AMGN Price
$285.57
Fair Value Price
$299.11
Market Cap
$152.37B
52 Week Low
$209.00
52 Week High
$296.67
P/E
22.81x
P/B
41.71x
P/S
4.58x
PEG
1.22x
Dividend Yield
2.72%
Revenue
$26.33B
Earnings
$6.84B
Gross Margin
75.8%
Operating Margin
34.39%
Profit Margin
26%
Debt to Equity
16.44
Operating Cash Flow
$10B
Beta
0.7
Next Earnings
Feb 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A

AMGN Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Zen Score

Industry Average (46)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMGN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AMGN ($285.57) is undervalued by 4.53% relative to our estimate of its Fair Value price of $299.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AMGN ($285.57) is not significantly undervalued (4.53%) relative to our estimate of its Fair Value price of $299.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AMGN ($285.57) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more AMGN due diligence checks available for Premium users.

Be the first to know about important AMGN news, forecast changes, insider trades & much more!

AMGN News

Valuation

AMGN fair value

Fair Value of AMGN stock based on Discounted Cash Flow (DCF)
Price
$285.57
Fair Value
$299.11
Undervalued by
4.53%
AMGN ($285.57) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMGN ($285.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMGN ($285.57) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AMGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
22.81x
Industry
32.03x
Market
21.39x
AMGN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AMGN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

AMGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
41.71x
Industry
5.63x
AMGN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AMGN price to earnings growth (PEG)

For valuing profitable companies with growth potential
AMGN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

AMGN's financial health

Profit margin

Revenue
$6.7B
Net Income
$2.1B
Profit Margin
32.2%
AMGN's Earnings (EBIT) of $9.06B... subscribe to Premium to read more.
Interest Coverage Financials
AMGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$63.7B
Liabilities
$60.0B
Debt to equity
16.44
AMGN's short-term assets ($24.06B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMGN's long-term liabilities ($45.72B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMGN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AMGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$3.0B
Investing
-$267.0M
Financing
$1.6B
AMGN's operating cash flow ($9.88B)... subscribe to Premium to read more.
Debt Coverage Financials

AMGN vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
AMGN$152.37B-0.07%22.81x41.71x
BMY$169.84B-0.06%25.85x5.20x
SNY$118.57B-2.13%17.49x1.65x
GILD$112.22B+1.91%33.51x5.32x
NVS$198.45B-0.16%9.35x3.26x

Amgen Stock FAQ

What is Amgen's quote symbol?

NASDAQ: AMGN) Amgen trades on the NASDAQ under the ticker symbol AMGN. Amgen stock quotes can also be displayed as NASDAQ: AMGN.

If you're new to stock investing, here's how to buy Amgen stock.

What is the 52 week high and low for Amgen (NASDAQ: AMGN)?

(NASDAQ: AMGN) Amgen's 52-week high was $296.67, and its 52-week low was $209.00. It is currently -3.74% from its 52-week high and 36.64% from its 52-week low.

How much is Amgen stock worth today?

(NASDAQ: AMGN) Amgen currently has 533,579,206 outstanding shares. With Amgen stock trading at $285.57 per share, the total value of Amgen stock (market capitalization) is $152.37B.

Amgen stock was originally listed at a price of $13.53 in Dec 31, 1997. If you had invested in Amgen stock at $13.53, your return over the last 24 years would have been 2,010.18%, for an annualized return of 13.55% (not including any dividends or dividend reinvestments).

How much is Amgen's stock price per share?

(NASDAQ: AMGN) Amgen stock price per share is $285.57 today (as of Dec 8, 2022).

What is Amgen's Market Cap?

(NASDAQ: AMGN) Amgen's market cap is $152.37B, as of Dec 9, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Amgen's market cap is calculated by multiplying AMGN's current stock price of $285.57 by AMGN's total outstanding shares of 533,579,206.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.